185 related articles for article (PubMed ID: 31586142)
1. Association between genetic polymorphisms of NRF2, KEAP1, MAFF, MAFK and anti-tuberculosis drug-induced liver injury: a nested case-control study.
Chen S; Pan H; Chen Y; Lu L; He X; Chen H; Chen R; Zhan S; Tang S
Sci Rep; 2019 Oct; 9(1):14311. PubMed ID: 31586142
[TBL] [Abstract][Full Text] [Related]
2. Possible association of HMOX1 and NQO1 polymorphisms with anti-tuberculosis drug-induced liver injury: A matched case-control study.
Yang M; Zhang H; Tao B; Pan H; Lu L; Yi H; Tang S
J Clin Pharm Ther; 2019 Aug; 44(4):534-542. PubMed ID: 30776144
[TBL] [Abstract][Full Text] [Related]
3. Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients.
Nanashima K; Mawatari T; Tahara N; Higuchi N; Nakaura A; Inamine T; Kondo S; Yanagihara K; Fukushima K; Suyama N; Kohno S; Tsukamoto K
Tuberculosis (Edinb); 2012 May; 92(3):253-9. PubMed ID: 22341855
[TBL] [Abstract][Full Text] [Related]
4. Association of LEPR polymorphisms with predisposition and inflammatory response in anti-tuberculosis drug-induced liver injury: A pilot prospective investigation in Western Chinese Han population.
Zhao Z; Peng W; Zhou J; Zhou Y; Liu T; Bai H; Wu Q; Song J; Wu L; Song X; Ying B
Infect Genet Evol; 2019 Nov; 75():103970. PubMed ID: 31325611
[TBL] [Abstract][Full Text] [Related]
5. The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study.
Chen R; Zhang Y; Tang S; Lv X; Wu S; Sun F; Xia Y; Zhan SY
J Clin Pharm Ther; 2015 Feb; 40(1):110-5. PubMed ID: 25250564
[TBL] [Abstract][Full Text] [Related]
6. The association between BACH1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese cohort.
Zhang H; Qian H; Tao B; Yang M; Gong J; Yi H; Tang S
Infect Genet Evol; 2018 Dec; 66():217-221. PubMed ID: 30316884
[TBL] [Abstract][Full Text] [Related]
7. The A/A Genotype of XPO1 rs4430924 Is Associated With Higher Risk of Antituberculosis Drug-Induced Hepatotoxicity in Chinese Patients.
He X; Zhang H; Tao B; Yang M; Chen H; Lu L; Yi H; Pan H; Tang S
J Clin Pharmacol; 2019 Jul; 59(7):1014-1021. PubMed ID: 30817003
[TBL] [Abstract][Full Text] [Related]
8. Lack of association between genetic polymorphisms of CYP3A4, CYP2C9 and CYP2C19 and antituberculosis drug-induced liver injury in a community-based Chinese population.
Tang SW; Lv XZ; Chen R; Wu SS; Yang ZR; Chen DF; Zhan SY
Clin Exp Pharmacol Physiol; 2013 May; 40(5):326-32. PubMed ID: 23469989
[TBL] [Abstract][Full Text] [Related]
9. Is anti-tuberculosis drug-induced hepatotoxicity due to a change in pharmacokinetics caused by alterations in antioxidant gene expression and polymorphisms in the
Ji G; Huang W; He J
Int J Clin Pharmacol Ther; 2020 Feb; 58(2):67-73. PubMed ID: 31670652
[TBL] [Abstract][Full Text] [Related]
10. Genetic Polymorphisms in Antioxidant Enzymes Modulate the Susceptibility of Idiosyncratic Antituberculous Drug-Induced Liver Injury and Treatment Outcomes in Patients with Tuberculosis.
Sun Q; Sha W; Liu HP; Wang P; Liu ZB; Sun WW; Xiao HP
Pharmacotherapy; 2020 Jan; 40(1):4-16. PubMed ID: 31742742
[TBL] [Abstract][Full Text] [Related]
11. Association of ABO blood group and antituberculosis drug-induced liver injury: A case-control study from a Chinese Han population.
Tao B; Yang M; Chen H; Pan H; Liu W; Yi H; Tang S
J Clin Pharm Ther; 2020 Aug; 45(4):638-645. PubMed ID: 32259340
[TBL] [Abstract][Full Text] [Related]
12. Small MAF genes variants and chronic myeloid leukemia.
Martínez-Hernández A; Gutierrez-Malacatt H; Carrillo-Sánchez K; Saldaña-Alvarez Y; Rojas-Ochoa A; Crespo-Solis E; Aguayo-González A; Rosas-López A; Ayala-Sanchez JM; Aquino-Ortega X; Orozco L; Cordova EJ
Eur J Haematol; 2014 Jan; 92(1):35-41. PubMed ID: 24118457
[TBL] [Abstract][Full Text] [Related]
13. Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han.
Chen G; Wu SQ; Feng M; Wang Y; Wu JC; Ji GY; Zhang MM; Liu QQ; He JQ
Int J Immunopathol Pharmacol; 2017 Dec; 30(4):434-438. PubMed ID: 28934901
[TBL] [Abstract][Full Text] [Related]
14. Transforming growth factor-beta 1 polymorphisms and anti-tuberculosis drug-induced liver injury. Polymorphisms in TGFβ1 and its relationship with anti-tuberculosis drug-induced liver injury.
Wu S; Wang Y; Zhang M; Wang M; He JQ
Therapie; 2019 Jun; 74(3):399-406. PubMed ID: 30093157
[TBL] [Abstract][Full Text] [Related]
15. CYP7A1, BAAT and UGT1A1 polymorphisms and susceptibility to anti-tuberculosis drug-induced hepatotoxicity.
Chen R; Wang J; Tang SW; Zhang Y; Lv XZ; Wu SS; Yang ZR; Xia YY; Chen DF; Zhan SY
Int J Tuberc Lung Dis; 2016 Jun; 20(6):812-8. PubMed ID: 27155186
[TBL] [Abstract][Full Text] [Related]
16. Association between NR1I2 polymorphisms and susceptibility to anti-tuberculosis drug-induced hepatotoxicity in an Eastern Chinese Han population: A case-control study.
Yang M; Pan H; Chen H; Liu W; Lu L; He X; Yi H; Tang S
Infect Genet Evol; 2020 Sep; 83():104349. PubMed ID: 32387752
[TBL] [Abstract][Full Text] [Related]
17. The role of the genetic variant FECH rs11660001 in the occurrence of anti-tuberculosis drug-induced liver injury.
Zhang M; Zhu J; Wang N; Liu W; Lu L; Pan H; He X; Yi H; Tang S
J Clin Pharm Ther; 2022 Aug; 47(8):1276-1283. PubMed ID: 35470464
[TBL] [Abstract][Full Text] [Related]
18. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
Wang PY; Xie SY; Hao Q; Zhang C; Jiang BF
Int J Tuberc Lung Dis; 2012 May; 16(5):589-95. PubMed ID: 22409928
[TBL] [Abstract][Full Text] [Related]
19. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China.
Shang P; Xia Y; Liu F; Wang X; Yuan Y; Hu D; Tu D; Chen Y; Deng P; Cheng S; Zhou L; Ma Y; Zhu L; Gao W; Wang H; Chen D; Yang L; He P; Wu S; Tang S; Lv X; Shu Z; Zhang Y; Yang Z; Chen Y; Li N; Sun F; Li X; He Y; Garner P; Zhan S
PLoS One; 2011; 6(7):e21836. PubMed ID: 21750735
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms in PXR and NF-κB1 influence susceptibility to anti-tuberculosis drug-induced liver injury.
Zhang J; Zhao Z; Bai H; Wang M; Jiao L; Peng W; Wu T; Liu T; Chen H; Song X; Wu L; Hu X; Wu Q; Zhou J; Song J; Lyv M; Ying B
PLoS One; 2019; 14(9):e0222033. PubMed ID: 31490979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
